Emerald Advisers LLC Has $1.10 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Emerald Advisers LLC cut its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 41.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 49,750 shares of the company's stock after selling 35,809 shares during the quarter. Emerald Advisers LLC's holdings in Teva Pharmaceutical Industries were worth $1,096,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $50,000. Ameliora Wealth Management Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at $66,000. IFP Advisors Inc raised its holdings in shares of Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after buying an additional 1,960 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in Teva Pharmaceutical Industries during the 4th quarter worth about $104,000. Finally, Assetmark Inc. lifted its position in Teva Pharmaceutical Industries by 1,370.3% during the 4th quarter. Assetmark Inc. now owns 5,205 shares of the company's stock worth $115,000 after buying an additional 4,851 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Analyst Ratings Changes

TEVA has been the subject of a number of research analyst reports. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. Bank of America dropped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, March 19th. UBS Group dropped their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Finally, Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $23.43.

Remove Ads

Teva Pharmaceutical Industries Stock Down 0.4 %

Shares of Teva Pharmaceutical Industries stock opened at $16.18 on Monday. The business has a fifty day simple moving average of $17.79 and a 200 day simple moving average of $18.21. The stock has a market cap of $18.34 billion, a PE ratio of -11.16, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.